Malaria is one of the major public health problems of the country. Factors responsible for reemergence of malaria in India was due to emergence and spread of chloroquine resistant Plasmodium falciparum strains across the country coupled with steady rise in insecticide resistance of the vector mosquitoes. Very little is known about the drug resistance status of P. falciparum in India. As per National Vector Borne Diseases Control Programme (NVBDCP), chloroquine is the drug of choice for uncomplicated P. falciparum cases and the combination of Artesunate and Sulfadoxine-Pyrimethamine (SP) is being used to treat the documented chloroquine-resistant uncomplicated cases. To evaluate the comparative effectiveness and resistance profile of Chloroquine vis-à-vis Sulfadoxine-Pyrimethamine (SP) in uncomplicated Plasmodium falciparum cases as the first-line therapy a study was undertaken at the Malaria Clinic of Calcutta School of Tropical Medicine, Kolkata during the period from Material & Methods: Following WHO protocol 2003, a total of 100 parasitologically confirmed Plasmodium falciparum cases were recruited as per the recruitment criteria. Among them, 50 patients were given Chloroquine and another 50 patients were given SP. Eight patients were excluded or lost to follow-up during the follow-up period because of failure to follow the protocol.
M i z o r a m , N a g a l a n d , O r i s s a , Rajasthan, Tripura, Uttar Pradesh, K a r n a t a k a , We s t B e n g a l , a n d A n d a m a n N i c o b a r I s l a n d s . I n West Bengal, during 1982-1988, Pandeya et al. 2 reported one R-III focus in Purulia and two R-III foci in Jalpaiguri. In recent years multidrug-resistant P. falciparum malaria has also been reported from various countries. Very little is known about the drug resistance status of P. falciparum in India. As per NVBDCP, chloroquine is the drug of choice for uncomplicated P . f a l c i p a r u m c a s e s a n d t h e combination of Artesunate and S u l f a d o x i n e -P y r i m e t h a m i n e i s b e i n g u s e d t o t r e a t t h e documented Chloroquine-resistant uncomplicated cases. There has been a steady rise in the proportion of recurrent P. falciparum cases (following use of recommended doses of chloroquine) attending the Malaria Clinic of School of Tropical Medicine, Kolkata (32.7% in 2001 and 66.5% in 2005). A significant proportion of recurrent P. falciparum c a s e s a r e d u e t o c h l o r o q u i n e resistance. 3 With continued use of chloroquine as first-line of therapy, the number of people with RI resistance and consequently the parasite burden in the community are also increasing. This results in increased transmission of P. f a l c i p a r u m i n t h e c o m m u n i t y .
Recently deaths due to P. falciparum malaria have been recorded in Kolkata, foothills of Purulia and certain Tea Estates of Dooars area of Jalpaiguri (Government data). While Chloroquine remains the first-line drug for uncomplicated P. falciparum malaria as per NVBDCP, a section of doctors, in private as well as in government sector, are using the Artemisinin derivatives and Quinine indiscriminately to treat uncomplicated P. falciparum malaria cases. Injudicious use of such reserved antimalarial drugs might lead to development of rapid resistance against them. In endemic areas it's difficult to differentiate "recrudescence" and "re-infection" clinically and/or parasitologically. This prompted us to undertake a p i l o t s t u d y t o e va l u a t e t h e e f f e c t i v e n e s s a n d r e s i s t a n c e profile of Chloroquine vis-à-vis Sulfadoxine-Pyrimethamine in u n c o m p l i c a t e d P l a s m o d i u m falciparum cases as the first-line therapy.
Patients and Methods
Study sites: The present study was undertaken at the Malaria Clinic of Calcutta School of Tropical Me dici n e, K olk a t a du ri n g t h e period from July 2007 to December 2007 under Ward no. 44 of Kolkata Municipal Corporation, Kolkata.
Figs. 1 and 2 : Thick & thin blood smear showing Giemsa stained Plasmodium falciparum ring under oil immersion with 100X magnification
Patients: A total of 100 patients were enrolled in this study (50 p a t i e n t s e a c h i n C h l o r o q u i n e and Sulfadoxine-Pyrimethamine group). The patients of confirmed Plasmodium falciparum malaria from Malaria Clinic were randomly screened and finally recruited for the study using following inclusion and exclusion criteria. 
Classification of Therapeutic Response According to WHO Protocol 2003
There are three categories of therapeutic responses, 23,24 namely 'Early Treatment Failure' (ETF), 'Late Treatment Failure' (LTF) a n d 'A d e q u a t e C l i n i c a l a n d Parasitological Response (ACPR)'. These are defined as follows:
Early Treatment Failure (ETF) if the patient develops one of the four conditions during the first three days of follow up. A d e q u a t e C l i n i c a l a n d Parasitological Response (ACPR) : Absence of parasitaemia on Day 28 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure Fever Clearance Time (FCT) : This is the time from beginning of antimalarial treatment until the patient is apyrexial. This is of two types -FCTa and FCTb. FCTa is when temperature first falls below 37.5°C (99.5°F) and FCTb is when the temperature falls and remains below 37.5°C for 24 hours. In this study FCTa has consistently been taken into consideration.
Parasite Clearance Time (PCT):
It is the time between beginning the antimalarial treatment and the first negative blood slide.
Results
In the present study a total of 100 parasitologically confirmed There were 87 male patients (87%) and 13 female patients (13%). In the Chloroquine arm there were 42(84%) male patients and 8 (16%) female patients and in the Sulfadoxine-Pyrimethamine arm there were 45 male patients (90%) and 5 (10%) female patients.
The mean age at presentation was 32.4 years (Range 10-62, Median 30). For Chloroquine arm the mean age was 33.3 years (Range 10-62, Median 32.5) and for Sulfadoxine-P y r i m e t h a m i n e a r m t h e m e a n age was 31.5 years (Range 13-62, Median 29.5).
According to the study protocol, Plasmodium falciparum parasitemic patients with fever of >37.5°C (>99.5°F) or with history of fever within the previous 24 hrs were enrolled. On Day 0, the mean temperature in the Chloroquine group was 100.56°F (range 96-103.6°F) and that of Sulfadoxine-Pyrimethamine group was 100.63 0 F (range 96.8-103.8°F). Six patients were afebrile at day 0; 4 in the Chloroquine group and 2 in the Sulfadoxine-Pyrimethamine group. All of them had a history of fever within the previous 24 hours.
T h e m e a n F e ve r C l e a r a n c e Time (FCT) of 93 patients was 29.9 hours (range 24-72 hours) a n d t h a t o f C h l o r o q u i n e a n d Sulfadoxine-Pyrimethamine arm was 28.8±13.145 hours (median 24 hours; range 24-72 hours), and 31±14.818 hours (median 24 hours; range 24-72 hours) respectively. The difference of mean FCT of Chloroquine and Sulfadoxine-Pyrimethamine group was not statistically significant (p = 0.45).
On day 0, the mean parasite count of Chloroquine group was 10409.6 per µL (range 1040-95840 /µL) and that of Sulfadoxine-Pyrimethamine group was 9984.04 /µL (range 1040-72000/µL) The mean Parasite Clearance Time (PCT) of 94 patients was 72 hours (range 48-168 hours) and that of Chloroquine and Sulfadoxinepyrimethamine arm was 82.7 ± 40.287 hours (range 48-168 hours) and 61.3 ± 25.423 hours (range 48-168 hours), respectively. The difference of mean PCT of chloroquine and Sulfadoxine-Pyrimethamine group was statistically significant (p value = 0.003).
In the chloroquine arm, out of the 50 patients, total 30 patients (60%) showed Adequate Clinical and Parasitological Response (ACPR), 15 patients (30%) showed Late 
Discussion

Chloroquine resistance status
In our study, it was observed that in the Chloroquine group o u t o f 5 0 p a t i e n t s , 3 0 ( 6 0 % ) showed Adequate Clinical and Parasitological Response (ACPR), 15 (30%) had Late Treatment Failure (LTF) and remaining 5 (10%) were lost during the follow-up period.
Similar studies with Chloroquine conducted in different parts of the world showed varied results. Those are described below:
In 2000 
Sulfadoxine-Pyrimethamine resistance status
In the present study, out of 50 patients in the Sulfadoxine-Pyrimethamine (SP) group, 46 (92%) showed Adequate Clinical a n d Pa r a s i t o l o g i c a l R e s p o n s e (ACPR) and only one (2%) had Late Treatment Failure (LTF) and 3 patients (6%) were lost during follow up period.
In Pakistan, Khan et al 8 showed four to 25% of cases were resistant to sulfadoxine-pyrimethamine. A r e c e n t s t u d y i n 2 0 0 7 -0 8 b y Maji et al 7 (unpublished data) documented that in Kalchini Block, Jalpaiguri, the treatment failure rate of Sulfadoxine-Pyrimethamine was 19.5% (ETF 13% and LTF 6.5%) and the ACPR was 80.5%. In Nagrakata Block of the same district, the treatment failure rate of Sulfadoxine-Pyrimethamine was 12% (ETF 2% & LTF 10%) and the ACPR was 88%. Bijil et al 16 (2000) reported 26% sulfadoxinepyrimethamine resistant cases in Africa. Maguire et al 10 (2002) in Central Java, Indonesia reported 22% treatment failures to SP. Almost similar results were observed in a study of SP resistance from Tanzania by Mugittu et al (2005) . 17 They had documented 50.9% ACPR at Day 28 and 17.1% and 24.1% of clinical and parasitological failure respectively after 28 days of follow up. In Malawi, Plowe et al 18 (2004) documented treatment failure rate of 20% in SP treated group. Checchi et al 11 in Harper, southwest Liberia reported SP failure rate of 51.5%. In Gambia, Bojang et al 19 showed ETF was 10.68% and LTF was 10% in SP treated patients. In Gambia another study by Muller e t a l 2 0 s h o we d E T F & LT F i n Sulfadoxine-Pyrimethamine group were 17% and 14% respectively. In Uganda, Talisuna et al 21 
